NCT01945021 2021-02-21Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLCPfizerPhase 2 Completed129 enrolled 16 charts
NCT01531361 2021-01-22Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF MutationsM.D. Anderson Cancer CenterPhase 1 Completed46 enrolled